指南与共识神经技术与安全MR

钆基对比剂注射后脑与身体钆沉积的关键问题、安全性及对欧洲药品管理局药物警戒与风险评估委员会建议暂停4种线性药物上市许可的临床建议

Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA's Pharmacovigilance and Risk Assessment Committee Recommendation for Suspension of the Marketing Authorizations for 4 Linear Agents.
指南 / 共识 · Invest Radiol · 2017-01-01

本文综述钆基对比剂安全性,重点讨论钆在脑和体内的沉积现象。2006年发现肾源性系统性纤维化后,欧洲药品管理局和美国食品药品监督管理局按风险对对比剂分层,使北美和欧洲未再发现新病例。2014年首次显示两种非离子线性螯合物钆双胺和钆喷酸葡胺注射后脑内长期沉积,促使关注体内分布、可能的脱螯合及沉积。综述围绕8个关键问题展开,专家建议除无合适替代品外,临床应从线性对比剂转向大环类对比剂。2017年3月10日,欧洲药品管理局药物警戒与风险评估委员会建议暂停4种线性钆对比剂静脉注射的上市许可,因有令人信服的证据表明注射后数月脑内有钆沉积。

要点

  • 线性钆对比剂可在体内发生脱螯合,导致钆在脑和身体沉积。
  • 专家建议除无合适替代品外,临床应从线性对比剂转向大环类对比剂。
  • 2017年3月10日欧洲药品管理局药物警戒与风险评估委员会建议暂停4种线性钆对比剂静脉注射的上市许可。

核心结论

  • 线性钆对比剂在体内发生脱螯合是钆沉积的原因,专家建议除无合适替代品外,临床应从线性对比剂转向大环类对比剂。

研究设计与样本

  • 综述,围绕8个关于钆在脑和身体沉积的关键问题展开讨论,未报告检索范围与纳入文献数量。

关键影像表现/征象

  • 2014年首次显示注射两种非离子线性螯合物钆双胺和钆喷酸葡胺后,钆在脑内长期沉积。
  • 有令人信服的证据表明注射这些线性对比剂后数月,脑内出现钆沉积。
  • 线性对比剂在体内发生脱螯合,导致钆沉积。

诊断标准与关键数值

  • 欧洲药品管理局药物警戒与风险评估委员会于2017年3月10日建议暂停4种线性钆对比剂静脉注射的上市许可:钆双胺(Omniscan)、钆弗塞胺(Optimark)、钆喷酸葡胺(Magnevist)和钆贝葡胺(MultiHance)。
  • 钆塞酸二钠(Primovist/Eovist)因满足重要诊断需求,以较低剂量用于肝脏成像,将继续可用。
  • 钆喷酸葡胺(Magnevist)的关节腔内注射剂型因钆浓度极低,将继续可用。

临床应用与阅片要点

  • 专家建议,除无合适替代品外,临床实践应从线性对比剂转向大环类对比剂。
  • 欧洲药品管理局药物警戒与风险评估委员会建议暂停4种线性钆对比剂静脉注射的上市许可,钆塞酸二钠和钆喷酸葡胺关节腔内注射剂型例外。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

For magnetic resonance, the established class of intravenous contrast media is the gadolinium-based contrast agents. In the 3 decades since initial approval, these have proven in general to be very safe for human administration. However, in 2006, a devastating late adverse reaction to administration of the less stable gadolinium-based contrast agents was identified, nephrogenic systemic fibrosis. The result of actions taken by the European Medicines Agency and the US Food and Drug Administration, stratifying the agents by risk and contraindicating specific agents in severe renal dysfunction, has led to no new cases being identified in North America or Europe. Subsequently, in 2014, long-term deposition in the brain of gadolinium was first shown, after administration of 2 nonionic linear chelates, gadodiamide, and gadopentetate dimeglumine. This has led to an intense focus on the question of in vivo distribution, possible dechelation, and subsequent deposition of gadolinium, together with substantial clarification of the phenomenon as well as stratification of the agents on this basis. This review focuses on 8 critical questions regarding gadolinium deposition in the brain and body, with the answers and discussion therein important for future regulatory decisions and clinical practice. It is now clear that dechelation of gadolinium occurs in vivo with the linear agents and is responsible for this phenomenon, with key experts in the field recommending, except where there is no suitable alternative, a shift in clinical practice from the linear to macrocyclic agents. In addition, on March 10, 2017, the Pharmacovigilance and Risk Assessment Committee of the European Medicines Agency recommended suspension of the marketing authorization for 4 linear gadolinium contrast agents-specifically Omniscan, Optimark, Magnevist, and MultiHance (gadodiamide, gadoversetamide, gadopentetate dimeglumine, and gadobenate dimeglumine)-for intravenous injection. Cited in the report was convincing evidence of gadolinium deposition in the brain months after injection of these linear agents. Primovist/Eovist (gadoxetic acid disodium) will remain available, being used at a lower dose for liver imaging, because it meets an important diagnostic need. In addition, a formulation of Magnevist for intra-articular injection will remain available because of its very low gadolinium concentration.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Runge VM. Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA's Pharmacovigilance and Risk Assessment Committee Recommendation for Suspension of the Marketing Authorizations for 4 Linear Agents. Invest Radiol. 2017. PMID: 28368880. doi:10.1097/RLI.0000000000000374

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。